Figure 2
![Figure 2. Duration of CHR and MCyR with bosutinib treatment. Duration of CHR (A) and MCyR (B) were determined by the evaluable population; patients entering the study in CCyR were excluded. As of the data cutoff, 77% of the evaluable patients who achieved a CHR still retained their response (124/172 [72%] imatinib-resistant and 65/75 [87%] imatinib-intolerant patients), with a median duration of CHR not reached. Of the evaluable patients who achieved a MCyR, 78% still retained their MCyR as of the data cutoff (73/101 [72%] imatinib-resistant and 36/39 [92%] imatinib-intolerant patients), with the median duration of MCyR not reached.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/17/10.1182_blood-2011-05-355594/4/zh89991179890002.jpeg?Expires=1735806883&Signature=w4OSscF2KL5vqtUldlkpMMG1YhJn3exsXcE1yn0StMvgCsmbmLZ5Wb0dskK-zKicb7XHdo4FqXL7Q4GqFJb89pWeB~V9GLBuTXb~75DPg9-3Nb0Tl1UONpgKg-q9MTy9mhQ0dAVCCPXoFiQgS1hZsn1xMnH8D2JVHPyY8sAKKvSSg6cxISO6LGNY2aQzUPqoXPXi9ZfRuDQ54WQHo5UA2hac171bhcbHZHEhjLfALMVKuDP2JusS3ePbUQAmwzyjRW0ALrOD-XnfaaYJ7tdwyzP-s9g1CdMg2aUi~XQeRxVsrAxoZLC2tqjEZBby6p04GUZbSEkBvwRpy7Ppx~wOJQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Duration of CHR and MCyR with bosutinib treatment. Duration of CHR (A) and MCyR (B) were determined by the evaluable population; patients entering the study in CCyR were excluded. As of the data cutoff, 77% of the evaluable patients who achieved a CHR still retained their response (124/172 [72%] imatinib-resistant and 65/75 [87%] imatinib-intolerant patients), with a median duration of CHR not reached. Of the evaluable patients who achieved a MCyR, 78% still retained their MCyR as of the data cutoff (73/101 [72%] imatinib-resistant and 36/39 [92%] imatinib-intolerant patients), with the median duration of MCyR not reached.
